1. Home
  2. MIRM vs WEN Comparison

MIRM vs WEN Comparison

Compare MIRM & WEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • WEN
  • Stock Information
  • Founded
  • MIRM 2018
  • WEN 1969
  • Country
  • MIRM United States
  • WEN United States
  • Employees
  • MIRM 334
  • WEN N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • WEN Restaurants
  • Sector
  • MIRM Health Care
  • WEN Consumer Discretionary
  • Exchange
  • MIRM Nasdaq
  • WEN Nasdaq
  • Market Cap
  • MIRM 2.2B
  • WEN 2.3B
  • IPO Year
  • MIRM 2019
  • WEN N/A
  • Fundamental
  • Price
  • MIRM $45.17
  • WEN $11.18
  • Analyst Decision
  • MIRM Strong Buy
  • WEN Hold
  • Analyst Count
  • MIRM 12
  • WEN 18
  • Target Price
  • MIRM $63.17
  • WEN $16.69
  • AVG Volume (30 Days)
  • MIRM 397.1K
  • WEN 5.1M
  • Earning Date
  • MIRM 05-07-2025
  • WEN 05-02-2025
  • Dividend Yield
  • MIRM N/A
  • WEN 7.81%
  • EPS Growth
  • MIRM N/A
  • WEN N/A
  • EPS
  • MIRM N/A
  • WEN 0.94
  • Revenue
  • MIRM $379,251,000.00
  • WEN $2,235,211,000.00
  • Revenue This Year
  • MIRM $33.98
  • WEN N/A
  • Revenue Next Year
  • MIRM $16.19
  • WEN $4.14
  • P/E Ratio
  • MIRM N/A
  • WEN $12.11
  • Revenue Growth
  • MIRM 69.31
  • WEN 2.18
  • 52 Week Low
  • MIRM $23.83
  • WEN $10.98
  • 52 Week High
  • MIRM $54.23
  • WEN $20.60
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 56.31
  • WEN 33.59
  • Support Level
  • MIRM $43.30
  • WEN $10.98
  • Resistance Level
  • MIRM $44.57
  • WEN $11.45
  • Average True Range (ATR)
  • MIRM 1.20
  • WEN 0.30
  • MACD
  • MIRM -0.05
  • WEN -0.02
  • Stochastic Oscillator
  • MIRM 54.57
  • WEN 13.99

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About WEN Wendy's Company (The)

The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $12.6 billion in 2024, narrowly edging Burger King ($11.5 billion) and clocking in well behind wide-moat McDonald's ($51.1 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spanned more than 7,200 total stores in 30 countries as of year-end 2024. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for roughly 94% of stores, and through franchise flipping and advisory fees.

Share on Social Networks: